J 2019

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study

MIRAVITLLES, Marc, Vladimir KOBLIZEK, Cristina ESQUINAS, Branislava MILENKOVIC, Adam BARCZYK et. al.

Základní údaje

Originální název

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study

Autoři

MIRAVITLLES, Marc (724 Španělsko, garant), Vladimir KOBLIZEK (203 Česká republika), Cristina ESQUINAS (724 Španělsko), Branislava MILENKOVIC (688 Srbsko), Adam BARCZYK (616 Polsko), Ruzena TKACOVA (703 Slovensko), Attila SOMFAY (348 Maďarsko), Kirill ZYKOV (643 Rusko), Neven TUDORIC (191 Chorvatsko), Kosta KOSTOV (100 Bulharsko), Zuzana ZBOŽÍNKOVÁ (203 Česká republika, domácí), Michal SVOBODA (203 Česká republika, domácí), Jurij SORLI (705 Slovinsko), Alvils KRAMS (428 Lotyšsko) a Arschang VALIPOUR (40 Rakousko)

Vydání

RESPIRATORY MEDICINE, LONDON, W B SAUNDERS CO LTD, 2019, 0954-6111

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.095

Kód RIV

RIV/00216224:14110/19:00110576

Organizační jednotka

Lékařská fakulta

UT WoS

000463627700022

Klíčová slova anglicky

COPD; CAT; mMRC; Comorbidities; GOLD classification

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 4. 9. 2019 15:03, Mgr. Tereza Miškechová

Anotace

V originále

Background: The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. Methods: The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy. Results: The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups. Conclusions: The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT > 10 is not equivalent to mMRC > 2 for assessing symptom burden.